Sarah E Wakeman
Dados Biográficos
| ID | 5535596 |
|---|---|
| NOME | Sarah E Wakeman |
| PRENOMES | Sarah E |
| SOBRENOME | Wakeman |
| ASSINATURA | WAKEMAN S E |
| AFILIAÇÕES | Massachusetts General Hospital |
| ORCID | 0000-0002-5475-2713 |
| VERIFICADO | Sim |
| TOTAL DE OBRAS | 17 |
| TOTAL DE CITAÇÕES | 6 |
| TOTAL COMO AUTOR | 17 |
| TOTAL COMO EDITOR | 0 |
| PRIMEIRO ANO DE PUBLICAÇÃO | 2008 |
| ANO MAIS RECENTE DE PUBLICAÇÃO | 2026 |
| ÍNDICE H | 1 |
The impact of substance use disorder and homelessness on hospital readmission
Hour Induction of Transdermal Buprenorphine to Buprenorphine Extended-Release
Buprenorphine is an effective treatment for opioid use disorder but can be slow when using a standard low-dose titration protocol to avoid precipitated withdrawal. This presents a substantial practical barrier in clinical practice. Recent low-dose induction strategies have attempted to simplify and shorten the process required for successful induction, including our own transdermal buprenorphine method, which achieves induction to sublingual bupr…
Development of a Clinical Decision-Making Framework to Address Parental Substance Use and Child Safety
Five main assessment areas will be discussed, including: 1). Safety of the child while substance use is occurring; 2). Safety of parental use patterns; 3). Parental treatment engagement; 4). Willingness to escalate treatment services; and 5). Stability of the home environment. We will present a clinical scenario to highlight how the framework is used as an aid to determine action planning with respect to immediate safety concerns, treatment escal…
Access to safer injection equipment among people who inject drugs utilizing medical services in an urban hospital in the United States
Injection drug use carries significant risks for injury and infection, particularly when injection supplies are reused or shared. Syringe service programs and pharmacy nonprescription sale of syringes minimize this risk by promoting access to supplies. This study aimed to characterize how individuals accessing medical care obtain supplies and the impact of perceived barriers to accessing safer injection supplies. One hundred and twenty participan…
Prevalence of Cannabis Use and Cannabis Route of Administration among Massachusetts Adults in Buprenorphine Treatment for Opioid Use Disorder
BACKGROUND: Recent prevalence estimates of cannabis use among individuals receiving medication treatment for OUD (MOUD) are lacking, and no study has characterized cannabis route of administration (cROA) in this population. These knowledge gaps are relevant because cannabis' effects and health outcomes vary by cROA and the availability and perceptions of cROA (e.g., vaping devices) are changing. METHODS: The Vaping In Buprenorphine-treated patien…
Performance Metrics of Substance Use Disorder Care Among Medicaid Enrollees in New York, New York
The results of this cross-sectional study suggest the need for progress in engaging patients in SUD treatment and improvement in the low performance of SUD care and limited variation in MMC plans in New York, New York. Improvement in the overall performance of SUD treatment in Medicaid potentially depends on general program improvements, not moving recipients among plans
Changes in characteristics of drug overdose death trends during the Covid-19 pandemic
Expanding Mail-Based Distribution of Drug-Related Harm Reduction Supplies Amid Covid-19 and Beyond
Expanding Mail-Based Distribution of Drug-Related Harm Reduction Supplies Amid COVID-19 and Beyond Brian S. Barnett MD, Sarah E. Wakeman MD, Corey S. Davis JD, MSPH, Jamie Favaro MSW, and Josiah D. Rich MD, MPH Affiliation Brian S. Barnett is with the Department of Psychiatry and Psychology, Center for Behavioral Health, Neurological Institute, Cleveland Clinic, Cleveland, OH. Sarah E. Wakeman is with the Division of General Internal Medicine, Ma…
Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder
Importance Although clinical trials demonstrate the superior effectiveness of medication for opioid use disorder (MOUD) compared with nonpharmacologic treatment, national data on the comparative effectiveness of real-world treatment pathways are lacking. Objective To examine associations between opioid use disorder (OUD) treatment pathways and overdose and opioid-related acute care use as proxies for OUD recurrence. Design, Setting, and Participa…
Use of promethazine, gabapentin and clonidine in combination with opioids or opioid agonist therapies among individuals attending a syringe service program
Relative Cost Differences of Initial Treatment Strategies for Newly Diagnosed Opioid Use Disorder
BACKGROUND: Relative costs of care among treatment options for opioid use disorder (OUD) are unknown. METHODS: We identified a cohort of 40,885 individuals with a new diagnosis of OUD in a large national de-identified claims database covering commercially insured and Medicare Advantage enrollees. We assigned individuals to 1 of 6 mutually exclusive initial treatment pathways: (1) Inpatient Detox/Rehabilitation Treatment Center; (2) Behavioral Hea…
Stigma as a fundamental hindrance to the United States opioid overdose crisis response
Alexander Tsai and co-authors discuss the role of stigma in responses to the US opioid crisis.
Barriers to Medications for Addiction Treatment
Why It's Inappropriate Not to Treat Incarcerated Patients with Opioid Agonist Therapy
Due to the criminalization of drug use and addiction, opioid use disorder is overrepresented in incarcerated populations. Decades of evidence supports opioid agonist therapy as a highly effective treatment that improves clinical outcomes and reduces illicit opioid use, overdose death, and cost. Opioid agonist therapy has been both studied within correctional facilities and initiated prerelease. It has been found to be beneficial, yet few incarcer…
The Inmate Exception and Reform of Correctional Health Care
Language and Addiction
Two recent articles in the American Journal of Public Health discussed the importance of educating trainees in social work1 and medicine2 in screening, brief intervention, and referral to treatment (SBIRT) technique for approaching patients with substance use disorders. In both articles the terms “substance use” and “substance abuse” were used somewhat interchangeably. Both articles contribute to the important recognition that training in addicti…
Literature in Brief
Language and Addiction
Two recent articles in the American Journal of Public Health discussed the importance of educating trainees in social work1 and medicine2 in screening, brief intervention, and referral to treatment (SBIRT) technique for approaching patients with substance use disorders. In both articles the terms “substance use” and “substance abuse” were used somewhat interchangeably. Both articles contribute to the important recognition that training in addicti…
Expanding Mail-Based Distribution of Drug-Related Harm Reduction Supplies Amid Covid-19 and Beyond
Expanding Mail-Based Distribution of Drug-Related Harm Reduction Supplies Amid COVID-19 and Beyond Brian S. Barnett MD, Sarah E. Wakeman MD, Corey S. Davis JD, MSPH, Jamie Favaro MSW, and Josiah D. Rich MD, MPH Affiliation Brian S. Barnett is with the Department of Psychiatry and Psychology, Center for Behavioral Health, Neurological Institute, Cleveland Clinic, Cleveland, OH. Sarah E. Wakeman is with the Division of General Internal Medicine, Ma…
The Inmate Exception and Reform of Correctional Health Care
Literature in Brief
Language and Addiction
Two recent articles in the American Journal of Public Health discussed the importance of educating trainees in social work1 and medicine2 in screening, brief intervention, and referral to treatment (SBIRT) technique for approaching patients with substance use disorders. In both articles the terms “substance use” and “substance abuse” were used somewhat interchangeably. Both articles contribute to the important recognition that training in addicti…
Why It's Inappropriate Not to Treat Incarcerated Patients with Opioid Agonist Therapy
Due to the criminalization of drug use and addiction, opioid use disorder is overrepresented in incarcerated populations. Decades of evidence supports opioid agonist therapy as a highly effective treatment that improves clinical outcomes and reduces illicit opioid use, overdose death, and cost. Opioid agonist therapy has been both studied within correctional facilities and initiated prerelease. It has been found to be beneficial, yet few incarcer…
The Inmate Exception and Reform of Correctional Health Care
Barriers to Medications for Addiction Treatment
Stigma as a fundamental hindrance to the United States opioid overdose crisis response
Alexander Tsai and co-authors discuss the role of stigma in responses to the US opioid crisis.
Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder
Importance Although clinical trials demonstrate the superior effectiveness of medication for opioid use disorder (MOUD) compared with nonpharmacologic treatment, national data on the comparative effectiveness of real-world treatment pathways are lacking. Objective To examine associations between opioid use disorder (OUD) treatment pathways and overdose and opioid-related acute care use as proxies for OUD recurrence. Design, Setting, and Participa…
Use of promethazine, gabapentin and clonidine in combination with opioids or opioid agonist therapies among individuals attending a syringe service program
Relative Cost Differences of Initial Treatment Strategies for Newly Diagnosed Opioid Use Disorder
BACKGROUND: Relative costs of care among treatment options for opioid use disorder (OUD) are unknown. METHODS: We identified a cohort of 40,885 individuals with a new diagnosis of OUD in a large national de-identified claims database covering commercially insured and Medicare Advantage enrollees. We assigned individuals to 1 of 6 mutually exclusive initial treatment pathways: (1) Inpatient Detox/Rehabilitation Treatment Center; (2) Behavioral Hea…
Changes in characteristics of drug overdose death trends during the Covid-19 pandemic
Expanding Mail-Based Distribution of Drug-Related Harm Reduction Supplies Amid Covid-19 and Beyond
Expanding Mail-Based Distribution of Drug-Related Harm Reduction Supplies Amid COVID-19 and Beyond Brian S. Barnett MD, Sarah E. Wakeman MD, Corey S. Davis JD, MSPH, Jamie Favaro MSW, and Josiah D. Rich MD, MPH Affiliation Brian S. Barnett is with the Department of Psychiatry and Psychology, Center for Behavioral Health, Neurological Institute, Cleveland Clinic, Cleveland, OH. Sarah E. Wakeman is with the Division of General Internal Medicine, Ma…
Prevalence of Cannabis Use and Cannabis Route of Administration among Massachusetts Adults in Buprenorphine Treatment for Opioid Use Disorder
BACKGROUND: Recent prevalence estimates of cannabis use among individuals receiving medication treatment for OUD (MOUD) are lacking, and no study has characterized cannabis route of administration (cROA) in this population. These knowledge gaps are relevant because cannabis' effects and health outcomes vary by cROA and the availability and perceptions of cROA (e.g., vaping devices) are changing. METHODS: The Vaping In Buprenorphine-treated patien…
Performance Metrics of Substance Use Disorder Care Among Medicaid Enrollees in New York, New York
The results of this cross-sectional study suggest the need for progress in engaging patients in SUD treatment and improvement in the low performance of SUD care and limited variation in MMC plans in New York, New York. Improvement in the overall performance of SUD treatment in Medicaid potentially depends on general program improvements, not moving recipients among plans
Access to safer injection equipment among people who inject drugs utilizing medical services in an urban hospital in the United States
Injection drug use carries significant risks for injury and infection, particularly when injection supplies are reused or shared. Syringe service programs and pharmacy nonprescription sale of syringes minimize this risk by promoting access to supplies. This study aimed to characterize how individuals accessing medical care obtain supplies and the impact of perceived barriers to accessing safer injection supplies. One hundred and twenty participan…
Hour Induction of Transdermal Buprenorphine to Buprenorphine Extended-Release
Buprenorphine is an effective treatment for opioid use disorder but can be slow when using a standard low-dose titration protocol to avoid precipitated withdrawal. This presents a substantial practical barrier in clinical practice. Recent low-dose induction strategies have attempted to simplify and shorten the process required for successful induction, including our own transdermal buprenorphine method, which achieves induction to sublingual bupr…
Development of a Clinical Decision-Making Framework to Address Parental Substance Use and Child Safety
Five main assessment areas will be discussed, including: 1). Safety of the child while substance use is occurring; 2). Safety of parental use patterns; 3). Parental treatment engagement; 4). Willingness to escalate treatment services; and 5). Stability of the home environment. We will present a clinical scenario to highlight how the framework is used as an aid to determine action planning with respect to immediate safety concerns, treatment escal…
The impact of substance use disorder and homelessness on hospital readmission
Medicine (13 obras) · Opioid Use Disorder Treatment (11 obras) · Psychiatry (10 obras) · Opioid (8 obras) · Internal Medicine (7 obras) · Opioid use disorder (7 obras) · Buprenorphine (5 obras) · Family medicine (5 obras) · Substance Abuse Treatment and Outcomes (5 obras) · HIV, Drug Use, Sexual Risk (4 obras)